about
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationPharmacotherapies for obesity: past, current, and future therapiesLong term pharmacotherapy for obesity and overweight: updated meta-analysis.Psychosocial interventions for the maintenance of weight loss in obese adultsMetformin for obesity or overweightInterventions for treating overweight or obesity in adults: an overview of systematic reviewsWeight loss interventions for chronic asthmaWeight loss interventions for chronic asthmaCannabinoid type 1 receptor antagonists for smoking cessationInterventions to change the behaviour of health professionals and the organisation of care to promote weight reduction in overweight and obese peopleMetformin for obesity or overweightCannabinoid type 1 receptor antagonists (rimonabant) for smoking cessationPsychosocial interventions for the maintenance of weight loss in obese adultsLong-term pharmacotherapy for obesity and overweightThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaborationObesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorshipPharmacotherapies for Overeating and Obesity.The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in ratsTackling obesity: new therapeutic agents for assisted weight loss.Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142.Obesity and preclinical changes of cardiac geometry and function.The endocannabinoid system: potential for reducing cardiometabolic riskSample size in obesity trials: patient perspective versus current practice.The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behaviorRimonabant: From RIO to Ban.Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome.The role of gastrointestinal vagal afferent fibres in obesity.Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats.Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal.Lifestyle-induced metabolic inflexibility and accelerated ageing syndrome: insulin resistance, friend or foe?Appetite suppressants, cardiac valve disease and combination pharmacotherapyCurrent pharmacotherapeutic concepts for the treatment of obesity in adults.Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.Devices for the treatment of obesity: will understanding the physiology of satiety unravel new targets for intervention?Medications for obesity.
P2860
Q21092360-0C3D8AC5-4055-46B9-8A8B-67CE982FDC21Q21296814-BE193846-8D54-407A-8E8C-795979489D7DQ22242086-A619F4FF-9198-415E-B962-B692A1502DB6Q24186273-369E4FA7-60A2-499E-984B-DE057D886E75Q24195145-D424B689-E120-4774-A177-B65986E778F1Q24200908-004808A1-EE4D-4598-9B91-269970FE7E42Q24202192-761EC96A-5673-4F5F-A865-2950C3F789B2Q24234138-028FFD99-8838-4346-92BE-156F9769C4DDQ24235611-87CF1E48-9BD8-4ACC-8A52-34EAF488F2B2Q24236596-6C8903E7-AA8E-4CD2-AE89-95DC55335DB1Q24236796-53AEA387-A16B-41A1-9B0D-37A80FCD7110Q24243186-10CC4D22-4337-4FFE-B80D-0D540B930C1CQ24243565-53A122E0-5BC9-4B06-B139-34511D144AA3Q24247723-F2B7CF4D-3424-4FB2-AB2F-AA565BE561D9Q27860581-9F6E5B38-E960-4029-AFF7-7750BA730FDEQ28475155-E143E732-3DEE-4885-9AB7-A6D5022C539DQ30351879-B194D7FF-57FE-47C1-8019-BFF8DFF9A5AFQ30355922-7D3F18B9-842B-46D1-93C5-EED485585A8AQ30401145-B33311BA-8A2E-4E80-9419-5A5DF6151428Q33509626-8D4DA0FD-2CBF-4A13-900D-6B8CF83107CBQ33635704-D09C1701-AE21-4378-A218-4D9E9D25FA2AQ33685011-C9F72B79-9885-4DEA-B538-2C7CEAB69F63Q33999727-2BDB2601-47BA-4EE6-9EE0-788D4FA03512Q34039120-90578756-1050-4660-8D74-305F2DB7D328Q34131412-E6488565-F724-40E5-8CC2-D08819AAFF50Q34202105-B3943A22-D0E8-4AE6-96E4-DF3A4776AC8BQ34449870-287CD84F-EA1F-4493-B2DF-33CED6D8EEBCQ35459617-8577FDDE-D233-407C-97AF-9E2732FC3A20Q35586638-E227DFAB-1726-46C2-A656-379E74FC0C40Q37163861-A18C871A-D8F6-4456-B1E3-94D7EA8139CFQ37182203-D2160F5C-A2DA-4F63-82F4-B7EA546F07DEQ37268774-193FD731-0CAE-4129-8C5A-DC4C3C699C5EQ37368688-AB305B67-FF1C-4067-A46E-CD259D1496E8Q37387204-3D3E7F56-CEDF-4176-A31B-824530A3F14FQ41957252-DD751C8B-7F29-463A-9813-0C149A8EC406Q43262052-06493C6E-8C03-474E-8711-5553CB9ECA2B
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Rimonabant for overweight or obesity
@ast
Rimonabant for overweight or obesity
@en
Rimonabant for overweight or obesity
@en-gb
Rimonabant for overweight or obesity
@nl
type
label
Rimonabant for overweight or obesity
@ast
Rimonabant for overweight or obesity
@en
Rimonabant for overweight or obesity
@en-gb
Rimonabant for overweight or obesity
@nl
prefLabel
Rimonabant for overweight or obesity
@ast
Rimonabant for overweight or obesity
@en
Rimonabant for overweight or obesity
@en-gb
Rimonabant for overweight or obesity
@nl
P2860
P1476
Rimonabant for overweight or obesity
@en
P2093
Charles Andr��
Cintia Curioni
P2860
P356
10.1002/14651858.CD006162.PUB2
P577
2006-10-18T00:00:00Z